30 Investor presentation Full year 2022 Pipeline supports significant grow strategic focus areas PHASE 1 NN1845 – GSI NN1471 – Pumpinsulin NN9041 – DNA Immunotherapy NN9541 – Oral GLP-1/GIP co-agonist NN9917 – SemaDapa FDC NN9904 – Once weekly oral sema NN9847 – Oral Amycretin NN6020 – DCR-AUD 1 NN6582 – LXR(a) NN6581 – MARC1 PHASE 2 NN9389 – FDC Sema – OW GIP NN9388 – Cagrisema NN9775 – PYY 1875 analogue NN7533 – Ndec NN9931 – Gilead NASH NN9500 – FGF-21 NASH NN6021 – Belcesiran NN6019 – ATTR Cardiomypathy PHASE 3 NN1535 – Icosema NN1436 – Insulin Icod NN9924 – Oral Semag NN9838 – Cagrisema NN9932 – Oral Semag NN9931 – Semaglutid NN6535 - Semaglutid NN6018 - Ziltivekimab NN7769 – Mim8 NN7535 - Etavopivat Other PHASE 3 tri SOUL - Oral semaglut FOCUS - Semaglutide FLOW - Semaglutide 1 STRIDE – Semaglutide STEP – Semaglutide 2 SELECT – Semaglutide Diabetes care Obesity care Rare blood disorders 1 Dicerna-Alcohol Use Disorder; 2 25 mg trial also initiated; 3 Study conducted in growth hormone disorders; 4 Submitted to EU/US/JP mg and 16 mg) tested in phase 2; PYY: Peptide YY; QW: Once-weekly; mAb: monocolonal antibody; GDF15: Growth differentiation fa Glucose Sensitive Insulin; HFpEF : heart failure with preserved ejection fraction; AD: Alzheimer’s Disease; FDC; Fixed -dose combinati
Download PDF file